CSL 311

Drug Profile

CSL 311

Alternative Names: CSL311; CSL311-anti-Beta Common

Latest Information Update: 03 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CSL
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists; Interleukin 3 receptor antagonists; Interleukin 5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Allergic asthma

Most Recent Events

  • 03 Sep 2018 Preclinical development is still ongoing in USA (CSL Behring pipeline, September 2018)
  • 01 Nov 2012 Preclinical trials in Allergic asthma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top